GLP-1 receptor agonists, such as semaglutide and liraglutide, are produced as sterile injectable medications, making contamination control critical. Any lapse in sterility can have severe consequences for patient safety. For example, in 2024, the FDA investigated a compounding facility after a patient found black particulate matter in a semaglutide vial. The investigation revealed that the facility had used non-sterile ingredients during manufacturing. This incident led the FDA to issue warnings to the facility about the dangers of administering a contaminated drug when the drug is supposed to be sterile. Read More >
